QBiotics CEO and board update

BRISBANE, 4 December 2025

QBiotics today announces that Chief Executive Officer and Managing Director, Stephen Doyle, along with Non-executive Chairman, Mark Fladrich, and Non-executive Director, Sergio Duchini, have resigned, effective 3 December 2025. The resignations follow the Company’s Annual General Meeting (AGM) on 25 November 2025, where it became clear that the outgoing Directors hold differing views on the Company’s strategic direction from those of the founders.

At the AGM, shareholders voted to preserve the founders’ continued Board representation, contrary to the recommendations of the outgoing Directors, reflecting majority support for the founders’ strategic direction.

In light of this outcome, and given that the changes they had been advocating did not have unequivocal support, the outgoing Directors concluded they could no longer continue in their roles. The outgoing Directors wish the Company, its management, employees and shareholders every success for the next phase of QBiotics’ development.

The Board thanks each of them for their contributions to the Company.

QBiotics has commenced the process of establishing new Board and executive arrangements and will update shareholders on progress as soon as practicable.

—ends—
 

FURTHER INFORMATION
DR. VICTORIA GORDON, NON-EXECUTIVE DIRECTOR
victoria.gordon@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
NOTES FOR EDITORS

ABOUT QBIOTICS
QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialisation to harness the power of nature to treat diseases of high unmet need. 

Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.

QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumours. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.

A veterinary formulation of tigilanol tiglate (STELFONTA^®) is approved for the treatment of canine mast cell tumours (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA^®.

Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.